Y-mAbs Therapeutics Quarterly Income Statements Chart
Quarterly
|
Annual
Y-mAbs Therapeutics Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | ||||||||||||||||||||||||||
| revenues | ||||||||||||||||||||||||||
| net product revenue | 19,025,000 | 20,904,000 | ||||||||||||||||||||||||
| license revenue | 500,000 | 500,000 | 500,000 | 15,000,000 | 1,000,000 | 2,000,000 | ||||||||||||||||||||
| total revenues | 19,525,000 | 20,904,000 | 18,461,000 | 22,798,000 | 19,931,000 | 23,363,000 | 20,454,000 | 20,751,000 | 20,251,000 | 31,447,000 | 12,537,000 | 10,797,000 | 10,486,000 | |||||||||||||
| cost of goods sold | 2,662,000 | 3,001,000 | 2,248,000 | 3,014,000 | 2,097,000 | 2,039,000 | 2,595,000 | 4,649,000 | 2,083,000 | 2,020,000 | 2,475,000 | 1,140,000 | 1,831,000 | 1,461,000 | 550,000 | 200,000 | 93,000 | |||||||||
| gross profit | 16,863,000 | 17,903,000 | ||||||||||||||||||||||||
| yoy | ||||||||||||||||||||||||||
| qoq | -5.81% | |||||||||||||||||||||||||
| gross margin % | ||||||||||||||||||||||||||
| operating costs and expenses | ||||||||||||||||||||||||||
| license royalties | 50,000 | 50,000 | 50,000 | 100,000 | ||||||||||||||||||||||
| research and development | 11,104,000 | 11,359,000 | 11,168,000 | 12,341,000 | 13,267,000 | 13,388,000 | 15,358,000 | 12,055,000 | 13,418,000 | 19,787,000 | 22,453,000 | 26,420,000 | 22,912,000 | 28,757,000 | 23,131,000 | 19,778,000 | 21,579,000 | 24,011,000 | 21,005,000 | 30,059,000 | 18,622,000 | 19,660,000 | 14,494,000 | 12,511,000 | 11,041,000 | 8,731,000 |
| selling, general, and administrative | 11,313,000 | 13,087,000 | 13,613,000 | 17,232,000 | 11,425,000 | 11,135,000 | 10,200,000 | 11,270,000 | 12,251,000 | 10,793,000 | 13,626,000 | 23,082,000 | 13,438,000 | 15,138,000 | 13,988,000 | 13,475,000 | 11,970,000 | |||||||||
| total operating costs and expenses | 22,467,000 | 24,446,000 | 27,029,000 | 32,587,000 | 26,839,000 | 26,562,000 | 28,203,000 | 27,974,000 | 27,752,000 | 32,600,000 | 38,554,000 | 50,742,000 | 38,181,000 | 45,356,000 | 37,669,000 | 33,663,000 | ||||||||||
| income from operations | -5,604,000 | -6,543,000 | -8,568,000 | -9,789,000 | -6,908,000 | -3,199,000 | -7,749,000 | -7,223,000 | -7,501,000 | -1,153,000 | -26,017,000 | -39,945,000 | -27,695,000 | -35,758,000 | -28,704,000 | -22,712,000 | -28,259,000 | -20,094,000 | -32,641,000 | -40,452,000 | -26,747,000 | -24,359,000 | -18,634,000 | -16,253,000 | -14,078,000 | -11,415,000 |
| yoy | -18.88% | 104.53% | 10.57% | 35.53% | -7.91% | 177.45% | -70.22% | -81.92% | -72.92% | -96.78% | -9.36% | 75.88% | -2.00% | 77.95% | -12.06% | -43.85% | 5.65% | -17.51% | 75.17% | 148.89% | 89.99% | 113.39% | ||||
| qoq | -14.35% | -23.63% | -12.47% | 41.71% | 115.94% | -58.72% | 7.28% | -3.71% | 550.56% | -95.57% | -34.87% | 44.23% | -22.55% | 24.57% | 26.38% | -19.63% | 40.63% | -38.44% | -19.31% | 51.24% | 9.80% | 30.72% | 14.65% | 15.45% | 23.33% | |
| operating margin % | ||||||||||||||||||||||||||
| other income | -15,500 | -11,000 | ||||||||||||||||||||||||
| interest and other income | 2,372,000 | 1,352,000 | 1,916,000 | 640,000 | 439,000 | 59,000 | 568,000 | |||||||||||||||||||
| income before income taxes | -3,232,000 | -5,191,000 | -6,652,000 | -9,149,000 | -6,469,000 | -793,000 | -7,560,000 | -6,123,000 | ||||||||||||||||||
| benefit from income taxes | 7,000 | 5,000 | 346,000 | 100,000 | 160,000 | 195,000 | 187,000 | 179,000 | ||||||||||||||||||
| net income | -3,239,000 | -5,196,000 | -6,998,000 | -9,249,000 | -6,629,000 | -988,000 | -7,747,000 | -6,302,000 | -6,390,000 | 1,157,000 | -27,526,000 | -36,893,000 | -28,858,000 | -19,933,000 | -32,832,000 | -40,393,000 | -26,179,000 | -23,922,000 | -18,036,000 | -15,934,000 | -14,060,000 | -11,426,000 | ||||
| yoy | -51.14% | 425.91% | -9.67% | 46.76% | 3.74% | -185.39% | -71.86% | -103.14% | -4.62% | 85.09% | -12.10% | -16.68% | 82.04% | 153.50% | 86.19% | 109.36% | ||||||||||
| qoq | -37.66% | -25.75% | -24.34% | 39.52% | 570.95% | -87.25% | 22.93% | -1.38% | -652.29% | -104.20% | 27.84% | -39.29% | -18.72% | 54.30% | 9.43% | 32.63% | 13.19% | 13.33% | 23.05% | |||||||
| net income margin % | ||||||||||||||||||||||||||
| other comprehensive income/ | ||||||||||||||||||||||||||
| foreign currency translation | -2,013,000 | -863,000 | -1,083,000 | 199,000 | 399,000 | -1,400,000 | 806,000 | 18,000 | -306,000 | 832,750 | 1,598,000 | 1,422,000 | 311,000 | 187,750 | 238,000 | 78,000 | 435,000 | -19,500 | -12,000 | -91,000 | 25,000 | 134,000 | -66,000 | 56,000 | 54,000 | 39,000 |
| comprehensive loss | -5,252,000 | -6,059,000 | -8,081,000 | -9,050,000 | -6,230,000 | -2,388,000 | -6,941,000 | -6,284,000 | -6,696,000 | -23,348,500 | -25,928,000 | -4,407,750 | -28,620,000 | -24,870,500 | -32,844,000 | -40,484,000 | -26,154,000 | -23,788,000 | -18,102,000 | -15,878,000 | -14,006,000 | -11,387,000 | ||||
| net income per share | -0.07 | -0.12 | -0.16 | -0.21 | -0.15 | -0.02 | -0.18 | -0.14 | -0.15 | -0.553 | -0.63 | -0.108 | -0.66 | -0.623 | -0.82 | -1.01 | -0.66 | -0.7 | -0.53 | -0.47 | -0.42 | -0.42 | ||||
| weighted-average common shares outstanding, basic and diluted | 45,318,028 | 45,104,476 | 44,626,943 | 44,022,356 | 43,779,456 | 43,645,388 | 43,620,532 | 43,663,112 | 43,671,589 | 43,718,351 | 43,598,350 | 40,187,173 | 39,972,174 | 39,753,583 | 34,371,927 | 34,193,666 | 34,193,666 | 28,772,384 | 27,330,579 | |||||||
| product revenue | 18,461,000 | 22,798,000 | 19,431,000 | 23,363,000 | 19,954,000 | 20,751,000 | 20,251,000 | 16,447,000 | 12,537,000 | 9,797,000 | 10,486,000 | 9,598,000 | 8,965,000 | 8,951,000 | 5,383,000 | |||||||||||
| other income/(loss) | ||||||||||||||||||||||||||
| interest and other income/ | 2,406,000 | 189,000 | 1,100,000 | 437,000 | 598,000 | 319,000 | ||||||||||||||||||||
| other comprehensive income | ||||||||||||||||||||||||||
| other income / (loss) | ||||||||||||||||||||||||||
| interest and other income / | 1,111,000 | -1,135,000 | -154,000 | -225,000 | -338,000 | |||||||||||||||||||||
| other comprehensive income / | ||||||||||||||||||||||||||
| gain from sale of priority review voucher | 62,010,000 | |||||||||||||||||||||||||
| interest and other loss | 2,310,000 | -1,509,000 | -1,186,000 | -373,000 | ||||||||||||||||||||||
| net income / | -41,131,000 | -28,068,000 | -22,937,000 | 33,413,000 | ||||||||||||||||||||||
| comprehensive income / | -39,709,000 | -27,757,000 | -22,859,000 | 33,848,000 | ||||||||||||||||||||||
| net income / (loss) per share attributable to common stockholders, basic | -0.94 | -0.64 | ||||||||||||||||||||||||
| weighted-average common shares outstanding, basic | 43,718,748 | 43,709,238 | 43,569,482 | 41,870,759 | ||||||||||||||||||||||
| net income / (loss) per share attributable to common stockholders, diluted | -0.94 | -0.64 | ||||||||||||||||||||||||
| weighted-average common shares outstanding, diluted | 43,718,748 | 43,709,238 | 43,569,482 | 44,383,791 | ||||||||||||||||||||||
| revenue | ||||||||||||||||||||||||||
| total revenue | 6,324,750 | 8,965,000 | 10,951,000 | |||||||||||||||||||||||
| licensing royalties | ||||||||||||||||||||||||||
| royalties | 210,000 | |||||||||||||||||||||||||
| net income/(loss) per share attributable to common stockholders, basic | -0.53 | 0.8 | ||||||||||||||||||||||||
| net income/(loss) per share attributable to common stockholders, diluted | -0.53 | 0.75 | ||||||||||||||||||||||||
| total operating cost and expenses | 33,642,000 | |||||||||||||||||||||||||
| operating expenses | ||||||||||||||||||||||||||
| general and administrative | 14,630,000 | 11,636,000 | 10,393,000 | 8,125,000 | 4,699,000 | 4,140,000 | 3,742,000 | 3,037,000 | 2,684,000 | |||||||||||||||||
| total operating expenses | 40,844,000 | 32,641,000 | 40,452,000 | 26,747,000 | 24,359,000 | 18,634,000 | 16,253,000 | 14,078,000 | 11,415,000 | |||||||||||||||||
| interest and other income / (expenses) | 109,250 | -191,000 | ||||||||||||||||||||||||
| other income/ |
We provide you with 20 years income statements for Y-mAbs Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Y-mAbs Therapeutics stock. Explore the full financial landscape of Y-mAbs Therapeutics stock with our expertly curated income statements.
The information provided in this report about Y-mAbs Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.